Dr. Ezra Cohen, from the University of Chicago, Discusses the Cabozantinib (XL184) EXAM Trial
OncLive TV
Dr. Alex Adjei, from Roswell Park Cancer Institute, on the Need for Targeted Therapy Education
Advertisement
Dr. Charles Ryan, from the UCSF Diller Family Comprehensive Cancer Center, on the COU-AA-302 Abiraterone Acetate Interim Analysis Results.
Dr. José Baselga, from Massachusetts General Hospital, on combining pertuzumab with trastuzumab
Dr. Neal Shore, from the Atlantic Urology Clinics, Discusses the Enzalutamide (MDV3100) AFFIRM Trial
Dr. Mary-Ellen Taplin, from Dana-Farber Cancer Institute, on Neoadjuvant Abiraterone Acetate and Leuprolide Acetate
Advertisement
Dr. Julie Brahmer, from the Sidney Kimmel Comprehensive Cancer Center, on the PD-1 Immunotherapy BMS-93655 Clinical Trial
Dr. Eric Larsen, from the Maine Children's Cancer Program, Discusses Outcomes for AYA Patients With Acute Lymphoblastic Leukemia
Dr. Raoul Concepcion, from Urology Associates, PC, Nashville, TN, Discusses New Prostate Cancer Therapies.
Dr. Maurie Markman, from Cancer Treatment Centers of America, on Awareness of Long-Term Chemotherapy Side Effects
Dr. Paul Sieber, from the Urological Association of Lancaster, on Managing Bone Health After the Introduction of ADT.
Krista Rubin, from Massachusetts General Hospital Cancer Center, on Understanding Ipilimumab's Toxicities.
Dr. Nancy Davidson, from the University of Pittsburgh Cancer Institute, on Screening for Ovarian Cancer
Dr. Leonard Gomella, form the Jefferson Kimmel Cancer Center, on the Impact of the New USPSTF PSA Rating.
Dr. Oliver Sartor, from Tulane Cancer Center, Discusses Prostate-Specific Antigen (PSA) Screening
Dr. Leonard Gomella, from the Jefferson Kimmel Cancer Center, on the Provenge IMPACT Trial Survival Benefit
Dr. Andrew Goy, from John Theurer Cancer Center, on Neoadjuvant Hormonal Therapy Plus Zytiga
Dr. Neil Spector, from Duke Cancer Institute, Explains Breast Cancer Heterogeneity
Dr. Stephen Ansell, from the Mayo Clinic, on Treating Patients With Waldenström Macroglobulinemia
Dr. Matthew Ellis, from Siteman Cancer Center, on Heterogeneity Impacting Biomarker Efficacy
Dr. Robert Dreicer, from the Cleveland Clinic, on Utilizing New Prostate Cancer Therapies
Dr. Harry Erba, from University of Michigan Health System, Discusses Molecular Monitoring for CML
Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Discusses PSA Velocity
Dr. Neil Spector, from Duke Cancer Institute, Emphasizes the Importance of Studying Tumor Microenvironments
Dr. Daniel Petrylak, from the Herbert Irving Comprehensive Cancer Center, Discusses the Future of Abiraterone Acetate
Dr. J. Michael Dixon, from Western General Hospital, Scotland, Advises Against Mastectomies
Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, Discusses Treatment Options for DLBCL
Dr. Oliver Sartor, from Tulane Cancer Center, Discusses a New Trial Combining Radium-223 and Provenge
Dr. Eric Sherman, from Memorial Sloan-Kettering Cancer Center, Discusses Vandetanib's Dosage and Precautions
Dr. Howard Sandler, from Cedars-Sinai Medical Center, Describes the RTOG 9408 Prostate Cancer Trial Results
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5